Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Non Operating Income (2016 - 2025)

KalVista Pharmaceuticals' Other Non Operating Income history spans 11 years, with the latest figure at $5.2 million for Q2 2025.

  • On a quarterly basis, Other Non Operating Income rose 3850.36% to $5.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was $8.8 million, a 321.31% increase, with the full-year FY2025 number at $4.8 million, up 3386.96% from a year prior.
  • Other Non Operating Income hit $5.2 million in Q2 2025 for KalVista Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for KALV hit a ceiling of $5.2 million in Q2 2025 and a floor of -$1.3 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged $1.4 million across 4 years, with a median of $1.3 million in 2024.
  • Biggest five-year swings in Other Non Operating Income: crashed 89.7% in 2021 and later surged 3850.36% in 2025.
  • Tracing KALV's Other Non Operating Income over 4 years: stood at $301000.0 in 2021, then crashed by 531.56% to -$1.3 million in 2023, then soared by 263.13% to $2.1 million in 2024, then skyrocketed by 146.01% to $5.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for KALV at $5.2 million in Q2 2025, $2.1 million in Q4 2024, and $1.6 million in Q3 2024.